CAFC Applies Collateral Estoppel Sua Sponte In XY v. Trans Ova Genetics

FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is a law firm dedicated to advancing ideas, discoveries, and innovations that drive businesses around the world. From offices in the United States, Europe, and Asia, Finnegan works with leading innovators to protect, advocate, and leverage their most important intellectual property (IP) assets.
In XY, LLC v. Trans Ova Genetics, L.C., Nos. 16-2054, 16-2136, a majority of the CAFC panel applied collateral estoppel sua sponte to an appeal from a district court action following its affirmance...
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

In XY, LLC v. Trans Ova Genetics, L.C., Nos. 16-2054, 16-2136 (Fed. Cir. May 23, 2018), a majority of the CAFC panel applied collateral estoppel sua sponte to an appeal from a district court action following its affirmance of an unpatentability finding by the PTAB of one of XY's patents in dispute in both actions.  The majority held that "an affirmance of an invalidity (unpatentability) finding, whether from a district court or the Board, has a collateral estoppel effect on all pending or co-pending actions," therefore, the issues on appeal from the district court were moot for this patent.  The patents-at-issue were directed to sorting methods for X- and Y- chromosome-bearing sperms cells for selective breeding purposes.  Further discussion of the decision can be found on Finnegan's Federal Circuit IP Blog.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More